You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-risk hepatocellular Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 24, 2023

Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

Not yet recruiting
  • Liver Transplant; Complications
  • +3 more
  • multi-kinase inhibitors in combination with bevacizumab
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023

Hepatocellular Carcinoma Trial in Chicago (Atezolizumab and Bevacizumab, Y90 + TKI)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Atezolizumab and Bevacizumab
  • Y90 + TKI
  • Chicago, Illinois
    Northwestern University
Nov 11, 2022

Liver Transplantation, Hepatocellular Carcinoma Trial in Kaohsiung

Recruiting
  • Liver Transplantation
  • Hepatocellular Carcinoma
    • Kaohsiung, Taiwan
      Kaohsiung Cheng Gang
    Oct 6, 2022

    Hepatocellular Carcinoma Trial in Changsha (HIPEC+tislelizumab + targeted therapy)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • HIPEC+tislelizumab + targeted therapy
    • Changsha, Hunan, China
      Hunan Provincial People's Hospital(The First Affiliated Hospital
    Sep 19, 2022

    Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC

    Not yet recruiting
    • Stage IB Hepatocellular Carcinoma AJCC v8
    • +2 more
    • Gainesville, Florida
    • +3 more
    Jun 15, 2022

    Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Adjuvant tislelizumab plus lenvatinib
    • Adjuvant tislelizumab
    • Nanning, China
      Jian-Hong Zhong
    Jun 11, 2023

    Hepatocellular Carcinoma Trial in Tianjin (ultrasonic testing)

    Recruiting
    • Hepatocellular Carcinoma
    • ultrasonic testing
    • Tianjin, Tianjin, China
      王芳
    Nov 20, 2023

    Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +5 more
    • TACE
    • Tislelizumab, Lenvatinib
    • Hangzhou, Zhejiang, China
      1# Banshan East Rd. Zhejiang cancer hospital
    Jun 17, 2023

    Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

    Recruiting
    • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Jan 4, 2023

    Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Nov 10, 2022

    Hepatocellular Carcinoma Trial (Donafenib + Tislelizumab)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Donafenib + Tislelizumab
    • (no location specified)
    Sep 15, 2022

    Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

    Not yet recruiting
    • Resectable Hepatocellular Carcinoma
    • (no location specified)
    Dec 12, 2022

    Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Anlotinib Hydrochloride
    • TACE
    • Lanzhou, Gansu, China
    • +3 more
    Jan 12, 2023

    Hepatocellular Carcinoma Trial in Shanghai (lenvatinib, TACE)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Shanghai, China
      Huashan hospital
    Jul 29, 2022

    Hepatocellular Carcinoma Trial in Shanghai (AK104, )

    Not yet recruiting
    • Hepatocellular Carcinoma
    • AK104
    • placebo
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Aug 4, 2022

    Hepatocellular Carcinoma Trial in Beijing (Autologous memory lymphocyte Injection (NewishT), low-dose group, Autologous memory

    Recruiting
    • Hepatocellular Carcinoma
    • Autologous memory lymphocyte Injection (NewishT), low-dose group
    • Autologous memory lymphocyte Injection (NewishT), high-dose group
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    May 30, 2022

    Proteome Multimarker Panel With Multiple Reaction Monitoring

    Not yet recruiting
    • Liver Cirrhosis
    • multiple reaction monitoring (MRM)-based multimarker panel
    • (no location specified)
    Mar 5, 2023

    Hepatocellular Carcinoma Trial in Hefei (Tislelizumab + Sitravatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • Tislelizumab + Sitravatinib
    • Hefei, Anhui, China
      Anhui province hospital
    Jul 27, 2022

    Hepatocellular Carcinoma Trial in Seoul (Non-contrast focused MRI)

    Recruiting
    • Hepatocellular Carcinoma
    • Non-contrast focused MRI
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Jan 6, 2023

    Hepatocellular Cancer, Liver Cirrhoses, Diagnoses Disease Trial in Tianjin (Diagnostic Sonazoid-CEUS and EOB-MRI)

    Recruiting
    • Hepatocellular Cancer
    • +2 more
    • Diagnostic Sonazoid-CEUS and EOB-MRI
    • Tianjin, Tianjin, China
      Tianjin Third Central Hospital
    Dec 11, 2022

    Hepatocellular Carcinoma, Chronic Hepatitis B Trial in Xiamen (NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined

    Recruiting
    • Hepatocellular Carcinoma
    • Chronic Hepatitis B
    • NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combined with interferon treatments
    • NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） treatments
    • Xiamen, Fujian, China
      Boheng Zhang
    Feb 7, 2023

    Hepatocellular Carcinoma Trial in Hangzhou (Anlotinib Hydrochloride)

    Terminated
    • Hepatocellular Carcinoma
    • Anlotinib Hydrochloride
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital of Medical School of Zhejiang Univ
    Aug 25, 2022

    Hepatocellular Carcinoma Trial in Tianjin (Fusion imaging contrast-enhanced ultrasound)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Fusion imaging contrast-enhanced ultrasound
    • Tianjin, Tianjin, China
      Tianjin Third Central Hospital
    Jul 3, 2021

    Hepatocellular Carcinoma inHigh-risk Prospective Cohort

    Recruiting
    • Liver Diseases
      • Singapore, Singapore
      • +13 more
      Aug 15, 2022